AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02749370
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
Trial: NCT00016861
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01259297
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 150/300 mg once daily
Trial: NCT01259297
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg
Trial: NCT01259297
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCTZ 12.5/25 mg
Trial: NCT01276015
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
Trial: NCT02644083
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02595060
Drug: inhaled molgramostim (rhGM-CSF)
RxNorm normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01519427
Drug: Akt inhibitor MK2206
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01519427
Drug: selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01750476
Drug: Mirena
RxNorm normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01750476
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01750476
Drug: Depo-Provera
RxNorm normalized name: Depo-Provera
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01951482
Drug: Pemetrexed/cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receive Pemetrexed/cisplatin every 21 days
Trial: NCT01951482
Drug: Bevacizumab and Pemetrexed/cisplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
Trial: NCT00978458
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00004865
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004865
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00592501
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
Trial: NCT03894904
Drug: Papaverine
RxNorm normalized name: Papaverine
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
Trial: NCT03894904
Drug: Rescue papaverine, as needed
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
Trial: NCT02014532
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
Trial: NCT03242759
Drug: nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug
Trial: NCT03242759
Drug: pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug
Trial: NCT00690937
Drug: Enteric coated sevelamer
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug treatment
Trial: NCT00690937
Drug: Colesevelam Cholestagel
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug comparator
Trial: NCT01395485
Drug: AMG 827 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
Trial: NCT01051388
Drug: Low-dose PPI (Rabeprazole sodium)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
Trial: NCT01051388
Drug: High-dose PPI (Rabeprazole sodium)
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
Trial: NCT02033551
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02033551
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02033551
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00418262
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
Trial: NCT03115801
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
Trial: NCT03115801
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Trial: NCT03115801
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Trial: NCT02203838
Drug: RBP-7000
RxNorm normalized name: COCAINE ESTERASE (RBP-8000)
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.
Trial: NCT00436215
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 5 mg/kg intravenous (IV) every two weeks
Trial: NCT00023907
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01659944
Drug: Eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT01659944
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT01929044
Drug: 654-II (anisodamine)
RxNorm normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg injection
Trial: NCT00005029
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03536429
Drug: ACETAZOLAMIDE oral capsule
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Trial: NCT02644525
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of imatinib 200mg PO is given
Trial: NCT02644525
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of imatinib 400mg PO is given
Trial: NCT02644525
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of imatinib 600mg PO is given
Trial: NCT02111824
Drug: Indocyanine Green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
Trial: NCT02222987
Drug: Terbogrel
RxNorm normalized name: Terbogrel
DrugBank: Terbogrel (DB12204)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222987
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00022711
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
Trial: NCT01937208
Drug: concurrent chemotherapy with radiation
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel plus cisplatin were used weekly in both arms
Trial: NCT00118170
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00002677
Drug: tributyrin
RxNorm normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03857750
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg
Trial: NCT01326650
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral vitamin D supplement of 100 micrograms for three years
Trial: NCT01345916
Drug: BDP DPI 2 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BDP DPI 2 months
Trial: NCT00830830
Drug: Hyalgan (sodium hyaluronate)
RxNorm normalized name: sodium hyaluronate Injection [Hyalgan]
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00371033
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dosage
Trial: NCT04261907
Drug: ASC09/ritonavir group
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
Trial: NCT04261907
Drug: lopinavir/ritonavir group
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
Trial: NCT00688493
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 x 50 mg tablets, single oral dose
Trial: NCT00688493
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 x 10 mg capsules, single oral dose
Trial: NCT00688493
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overencapsulated 400 mg capsule, single oral dose
Trial: NCT00688493
Drug: Placebo to match moxifloxacin and dapagliflozin
RxNorm normalized name: metformin and dapagliflozin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overencapsulated 400 mg capsule, single oral dose
Trial: NCT00772512
Drug: PF-04802540
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg capsule, single dose
Trial: NCT00772512
Drug: PF-04802540
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg capsule, single dose
Trial: NCT01139723
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00962065
Drug: LX4211 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A low dose of LX4211; daily oral intake for 28 days
Trial: NCT00962065
Drug: LX4211 High Dose
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A high dose of LX4211; daily oral intake for 28 days
Trial: NCT03601338
Drug: Bemiparin
RxNorm normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: second generation low molecular weight Heparin
Trial: NCT03475407
Drug: Ozurdex intravitreal injection
RxNorm normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk
Trial: NCT00404404
Drug: paclitaxel albumin-stabilized nanoparticle formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00440128
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel
Trial: NCT00440128
Drug: Casopitant/Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Casopitant/Docetaxel
Trial: NCT03042611
Drug: Rivoceranib
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02369835
Drug: Dakin's solution
RxNorm normalized name: Sodium Hypochlorite 0.5% Topical application Solution [DAKIN'S SOLUTION FULL STRENGTH]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply modified Dakin's solution (0.005 to 0.01%) topically
Trial: NCT02485366
Drug: Rejuvesol
RxNorm normalized name: Adenine/Inosine/Sodium Phosphate, Dibasic/Sodium Phosphate, Monobasic/Sodium Pyruvate 34 MG/50 ML-1.34 GM/50 ML-500 MG/50 ML-200 MG/50 ML-550 MG/50 ML Injection Injectable [REJUVESOL]
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood transfused during surgery will be treated with Rejuvesol.
Trial: NCT01713036
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
Trial: NCT00592358
Drug: paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
Trial: NCT02948777
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01539837
Drug: Deferiprone 20mg
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Trial: NCT01539837
Drug: Deferiprone 30mg
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Trial: NCT01099839
Drug: Miglitol
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03125746
Drug: LXI-15029
RxNorm normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
Trial: NCT03125746
Drug: LXI-15029+Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
Trial: NCT02889510
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7-week subcutaneous liraglutide once daily
Trial: NCT03799003
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously (IV)
Trial: NCT02690480
Drug: PD-0332991 (Palbociclib)
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first
Trial: NCT03539562
Drug: Morphine Sulfate and Promethazine
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate and promethazine
Trial: NCT01591746
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01255358
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)
Trial: NCT02157558
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive 180 mg fexofenadine